NCT04445233 (CO-HOST) is a clinical trial of COVID-19 IgM-IgG Rapid Test in COVID-19, sponsored by University of North Carolina, Chapel Hill.

Who is sponsoring NCT04445233?

NCT04445233 is sponsored by University of North Carolina, Chapel Hill.

What drugs are being tested in NCT04445233?

Interventions in NCT04445233: COVID-19 IgM-IgG Rapid Test.

Is NCT04445233 still recruiting?

NCT04445233 is currently completed. Last updated 27 April 2022.

Last reviewed 2022-04-27 · How we verify

NCT04445233: CO-HOST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID-19 Household Transmission Study

Completed Last updated 27 April 2022

What this trial tests

trial testing COVID-19 IgM-IgG Rapid Test in COVID-19 in 315 participants. Completed in 1 September 2021.

Timeline

29 April 2020

Primary endpoint
1 September 2021

1 September 2021

Quick facts

Lead sponsor	University of North Carolina, Chapel Hill
Status	Completed
Study type	OBSERVATIONAL
Enrollment	315
Start date	29 April 2020
Primary completion	1 September 2021
Estimated completion	1 September 2021
Sites	1 location across United States

Drugs / interventions tested

COVID-19 IgM-IgG Rapid Test

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

University of North Carolina, Chapel Hill

Who can join

1 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will test and follow persons quarantined at home after testing positive for SARS-CoV-2 (COV) aged 18 years and older and their household members aged 1 year and older. The purpose of this research study is to understand how often COVID-19 (Coronavirus Disease 2019) spreads in the household when someone who tests positive for the virus self-isolates at home. The purpose of the extension part of the study is to help us understand long-term immunity to COVID-19. We are interested in how our immune system might still protect us from COVID-19 even after antibody levels decrease or are no longer detected. We are also interested in how immunity to COVID-19 is different in kids vs. adults.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Practical strategies for SARS-CoV-2 RT-PCR testing in resource-constrained settings.
Muller MS, Chhetri SB, Basham C, Rapp T, et al · · 2021 · cited 8× · PMID 34280773 · DOI 10.1016/j.diagmicrobio.2021.115469
Assessment of the Field Utility of a Rapid Point-of-Care Test for SARS-CoV-2 Antibodies in a Household Cohort.
Churiwal M, Lin KD, Khan S, Chhetri S, et al · · 2021 · cited 4× · PMID 34818625 · DOI 10.4269/ajtmh.21-0592
Symptom burden, viral load, and antibody response to ancestral SARS-CoV-2 strain [D614G] in an outpatient household cohort.
Churiwal M, Tompkins K, Streeter G, Litel C, et al · · 2026 · PMID 41642857 · DOI 10.1371/journal.pone.0313467
High household transmission of SARS-CoV-2 in the United States: living density, viral load, and disproportionate impact on communities of color
Cerami C, Rapp T, Lin F, Tompkins K, et al · · 2021 · DOI 10.1101/2021.03.10.21253173
Practical strategies for SARS-CoV-2 RT-PCR testing in resource-constrained settings
Muller MS, Chhetri SB, Basham C, Rapp T, et al · · 2021 · DOI 10.1101/2021.02.18.21251999

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other University of North Carolina, Chapel Hill trials

Trials by the same sponsor.

NCT06841913 — Woodsmoke Exposure, Influenza Infection, and Nasal Immunity · Phase 4 · suspended
NCT07383428 — The INICIO-Guatemala Study · NA · not yet recruiting
NCT07528443 — Ultraprocessed Foods in Colombia · NA · not yet recruiting
NCT07507370 — CARED : A Novel Rapid Treatment Paradigm for Depression · NA · not yet recruiting
NCT07534254 — Piloting a Generative Artificial Intelligence Chatbot in a Mobile Weight Loss Program · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04445233 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of North Carolina, Chapel Hill
Last refreshed: 27 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04445233.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing